Loading…

Attendo ABATT.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Services to the Health Industry

Nordic provider of elderly and disability care services, operating care homes and home-care services mainly in Sweden and Nordics.

≈ A Nordic elderly/disability care operator like a smaller Genesis HealthcareMomentum leader 82
Mkt cap
$1.87B
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$5.04M
20-day average traded
Fwd P/E
16.9×
forward earnings
ROIC−WACC
+1.4 pp
WACC 6.1%
Hurdle
-7 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · SEKSEK 132.10
1D+0.1%
1W-0.8%
1M+12.6%
3M+12.9%
6M+15.5%
YTD+61.3%
1Y+62.1%
ATR %2.8%
52w lowhigh1.9% off high

What Attendo does

Nordic provider of elderly and disability care services, operating care homes and home-care services mainly in Sweden and Nordics.

In one line: A Nordic elderly/disability care operator like a smaller Genesis Healthcare.

Products and services

  • Elderly care homes
  • Home care services
  • Disability support services

Customers

  • Municipalities (payers)
  • Care recipients and families

Where it sits in the supply chain

  • Health Care
  • Care services
  • Elderly and disability residential/home…

What could go right

  • Aging Nordic population driving care demand
  • Municipal outsourcing of care services

What could go wrong

  • Public reimbursement rate/policy risk
  • Staffing shortages and wage inflation

Moat: narrow (regulatory licence, scale, installed base). Licensed care-provider status and scale in a publicly funded, contract-based Nordic welfare model, similar to peer Ambea.

Headquarters: Stockholm, Sweden · Founded: 1985 · Employees: 21,943

Named competitors

  • Ambea AMBEA.ST
  • Humana (private) private or unlisted
  • Vardaga (private) private or unlisted

Attendo at a glance

Size Attendo (ATT.ST) is a Sweden Health Care company (Services to the Health Industry) with a market value of $1.87B, the 86th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 132.10 on 18 Nov 2026.

Performance Over six months the shares gained 15.5%, against +34.0% for the median peer and +2.8% for the Sweden market (cap-weighted) — 3rd lowest of 6 in its peer set.

Growth Revenue grew 0.2% over the last twelve months (peer median +9.1%); the operating margin is 10.5% (peer median 11.1%).

Valuation It trades at 16.9× forward earnings against a peer median of 22.4× (2nd cheapest of 6).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.4 points above its cost of capital (6.1% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 134ATT.ST 113
Six months, rebased to 100: Attendo against the median of its 5 peers (local-currency closes).

Attendo financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 19.1BSEK 19.0BSEK 19.0BSEK 17.3BSEK 14.5B
Revenue growth—0%+10%+19%—
Gross profitSEK 2.00BSEK 3.20BSEK 2.77BSEK 2.38BSEK 1.52B
EBITDASEK 4.08BSEK 3.79BSEK 3.39BSEK 3.00BSEK 2.05B
Net incomeSEK 1.02BSEK 813MSEK 450MSEK 376M-SEK 45.0M
Free cash flowSEK 2.90BSEK 2.66BSEK 2.27BSEK 2.10BSEK 1.17B
Capital expenditureSEK 179MSEK 200MSEK 196MSEK 149MSEK 204M
Total debtSEK 16.8BSEK 16.4BSEK 16.7BSEK 14.7BSEK 14.8B

Quarterly statements and history in the cockpit →

Attendo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-20%0%+20%ASTH9729NRCPMEDGXATT.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Attendo is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%50×100×ASTH9729NRCPMEDGXATT.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Attendo is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%ASTH9729NRCPMEDGXATT.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Attendo is the large dot.

Attendo competitors and peer comparison

Head to head with its named competitors (ATT.ST vs AMBEA.ST)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Attendo ATT.ST$1.87B+15%0%10%16.9×1.7%
Ambea AMBEA.ST$1.59B+28%+11%9%15.2×1.1%

How Attendo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Attendo against its 5 peers (data as of 18 Nov 2026)
MeasureATT.STPeer medianRank in peer set
1-month return+12.6%+7.5%2nd highest of 6
6-month return+15.5%+34.0%3rd lowest of 6
Distance from 52-week high-1.9%-7.9%2nd highest of 6
Revenue growth (TTM)+0.2%+9.1%lowest of 6
Operating margin10.5%11.1%3rd lowest of 6
Forward P/E16.9×22.4×2nd cheapest of 6
Growth the price implies (Req g, 7 yrs)1.7%7.4%2nd least demanding of 6
Growth delivered (Del g)+9.1%+6.2%3rd highest of 6
Hurdle (Req g minus delivered)-7.4 pp+4.0 pp3rd least demanding of 6
ROIC minus cost of capital+1.4 pp+5.3 pp2nd lowest of 6
EV / EBITDA8.5×20.8×2nd cheapest of 5
Net debt / EBITDA3.9×2.4×2nd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Attendo ATT.STSweden$1.87B+15%0%10%16.9×1.7%+9.1%
Astrana Health ASTHUnited States$1.47B-24%+35%3%17.6×7.4%+35.9%
Tokai 9729.TJapan$559M+13%+4%6%12.7×-13.4%+6.2%
NRC Health NRCUnited States$555M+36%+3%11%26.4×11.2%+0.6%
Pro Medicus PME.AXAustralia$13.4B+52%+23%75%105.7×53.5%+31.0%
Quest Diagnostics DGXUnited States$28.6B+34%+9%15%22.4×7.2%+3.2%

Questions

Who are Attendo's main competitors?
Named competitors: Ambea (AMBEA.ST), Humana (private) (private or unlisted), Vardaga (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Astrana Health (ASTH), Tokai (9729.T), NRC Health (NRC), Pro Medicus (PME.AX), Quest Diagnostics (DGX).
Is Attendo expensive compared with its peers?
On forward p/e it trades at 16.9× against a peer median of 22.4×, 2nd cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Attendo stock performed?
Over six months to 18 Nov 2026 the shares returned +15.5% against +34.0% for the median peer; over one year +62.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.